Cervical human papilloma virus infection.
Conditions
Interventions
Intervention 1: Intervention group: Sinacurcumin 40 (each capsule contains 40 mg of nanomicelle curcumin) orally once a day for 6 months. Intervention 2: Control group: They will receive placebo for s
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Women with high-risk Pap smear and HPV results Age 30 to 65 years
Exclusion criteria
Exclusion criteria: Known immune deficiency or autoimmune disease HIV positive patients Long-term use of corticosteroids or immunosuppressants smoking Pregnancy Infection with CIN2 or CIN3 in cervical biopsy Use of anticoagulants such as heparin, aspirin, clopidogrel, dipyridamole, warfarin and ticlopidine History of allergies to turmeric or other drugs, foods and dyes Gallbladder stones or bile duct obstruction and diseases related to gastric acidosis or active gastrointestinal ulcers Candida, trichomoniasis, and other infections of the cervix or vaginitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clearance of human papillomavirus infection from the cervix. Timepoint: Before the intervention and 6 months later. Method of measurement: Detection and Typing of Human Papilloma Virus by PCR.;Diagnostic quality of cervical smear. Timepoint: Before the intervention and 6 months later. Method of measurement: Pap smear sampling from the cervix. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmaryam mohsenikia
Arak University of Medical Sciences
Outcome results
None listed